Unknown PHASE3 INTERVENTIONAL 2-arm NCT03940378

Treatment of Advanced Intrahepatic Cholangiocarcinoma (TAICC)

The Efficacy of Levamisole Hcl in Advanced Intrahepatic Cholangiocarcinoma . A Multicenter, Open, Randomized, Prospective Study

Sponsor: Anyang Tumor Hospital

Conditions ICC

Interventions Anlotinib Hydrochloride Capsules Levamisole Hydrochloride

Updated 5 times since 2019 Last updated: May 4, 2019 Started: Feb 1, 2019 Primary completion: Feb 1, 2023 Completion: Feb 1, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on ICC, this trial is ongoing. The trial is conducted by Anyang Tumor Hospital and has accumulated 5 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Mar 2023 — Jul 2024 [monthly]

Unknown Status PHASE3

Status: Recruiting → Unknown Status
Jan 2021 — Mar 2023 [monthly]

Recruiting PHASE3
Jun 2019 — Jan 2021 [monthly]

Recruiting PHASE3

First recorded

Feb 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Anyang Tumor Hospital
First Affiliated Hospital of Xinjiang Medical University
Luoyang Central Hospital
Nanyang Central Hospital
Sanmenxia Central Hospital
The First Affiliated Hospital of Zhengzhou University
Third People's Hospital of Jiaozuo
pinmei Group General Hospital

Data source: The First Affiliated Hospital of Zhengzhou University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Zhengzhou, China